Abstract: A percutaneous absorption preparation is disclosed. The percutaneous absorption preparation contains donepezil for treatment of dementia, wherein the preparation includes: (a) donepezil or its pharmaceutically acceptable salt as active component, (b) propylene glycol monocaprylate as solubilizer, and (c) styrene-isoprene-styrene block copolymer (“SIS”) as adhesive. The percutaneous absorption preparation has low skin irritation and high skin penetration.

Abstract: Provided are: a polypeptide having activity of 3-methyl-2-oxobutanoate hydroxymethyltransferase; a microorganism having increased activity of 3-methyl-2-oxobutanoate hydroxymethyltransferase; a composition for producing pantothenic acid and/or pantoic acid, comprising the polypeptide and/or the microorganism, and a pantothenic acid and/or pantoic acid production method comprising a step for culturing the microorganism.

Abstract: An apparatus for fixing an insert member in a mold includes a groove formed on the inner circumferential surface of the insert member, a coupling protrusion protruding from the mold so that the insert member is inserted over the coupling protrusion, at least one hook member coupled to the mold such that a hook member moves between a protrusion position and a retreat position, and a driving unit for moving the at least one hook member between the protrusion position and the retreat position, wherein when the hook member is located at the protrusion position, the one end of the hook member engages with the groove of the insert member, and when the hook member is located at the retreat position, the one end of the hook member disengages from the groove of the insert member.

Abstract: One aspect of the present disclosure is a pharmaceutical composition which includes (R)—N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first component and a cellulosic polymer as a second component, wherein the composition of one aspect of the present disclosure has a formulation characteristic in which crystal formation is delayed for a long time.

Abstract: A display device includes a display area, a peripheral area disposed outside the display area, and a sealing area disposed outside the peripheral area, a first base substrate, a second base substrate facing the first base substrate, a color filter layer disposed under the first base substrate, a bank layer disposed under the color filter layer, and a sealing member disposed between the bank layer and the second base substrate in the sealing area. The bank layer includes bank patterns defining an opening disposed at least in the sealing area, and the sealing member fills the opening. Each of the bank patterns includes a first surface adjacent to the color filter layer and a second surface opposite to the first surface and adjacent to the sealing member. A width of the second surface is greater than a width of the first surface.

Abstract: A method of manufacturing a stacked structure includes forming a first metal buffer layer including crystal grains on a base substrate, forming a second metal buffer material layer on the first metal buffer layer, and crystallizing the second metal buffer material layer to form a second metal buffer layer, wherein the second metal buffer material layer includes crystal grains, and a density of the crystal grains of the second metal buffer material layer is lower than a density of the crystal grains of the first metal buffer layer.

Abstract: The present invention relates to a novel adenoviral vector not including a replication competent adenovirus. A recombinant E1/E3/E4-deleted adenoviral vector, of the present invention, in which an antigenic protein and an E4orf6 gene are inserted in an E1 gene-deleted region, has adenovirus productivity, degree of antigen expression, neutralizing antibody production amount, and T cell induction ability that are similar to those of a control group, and thus can be effectively used as a carrier for various vaccines for diseases or anti-cancer vaccines.

Abstract: The present invention relates to a novel coronavirus recombinant spike protein, a polynucleotide encoding the same, a vector comprising the polynucleotide, and a vaccine for preventing or treating coronavirus infection, comprising the vector. The coronavirus recombinant spike protein of the present invention is stable and thereby not easily decomposed in cells, and effectively activates immune cells thereby resulting in a high antibody production amount and T cell reactivity. It was confirmed that the vector of the present invention exhibits a high antigen expression level and thereby has a high antibody production amount and T cell reactivity, has a long antibody production period and expression period, and does not show liver toxicity. Accordingly, the vector of the present invention can be helpfully used as a vaccine for preventing or treating coronavirus infection.

Abstract: The present disclosure relates to an acetohydroxy acid synthase variant, a polynucleotide encoding the variant, a microorganism including the variant, and a method of producing L-isoleucine using the microorganism.